Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
SGD Pharma
SGD Pharma
Activities:
Packaging
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Packaging
SGD Pharma unveils its latest sustainability report
The report states the achievements made so far, as well as the targets the company has set for the rest of 2024, as well as long-term sustainability goals
Manufacturing
SGD Pharma successfully trials hydrogen burners at its Saint-Quentin-Lamotte
SGD Pharma’s decarbonisation roadmap aims to reduce CO2 emissions from 2020 by 35% in 2030 and by 65% in 2040
Packaging
SGD Pharma awarded 2024 gold EcoVadis rating
SGD Pharma’s sustainability rating of 77 puts the business in the 98th percentile for manufacturers of glass and glass products
Drug Delivery
SGD Pharma introduces its new range of Type I tubular vials
SGD partner with Corning to announce its new range of type I injectable vials in tubular glass with an added external low-friction coating
Packaging
SGD Pharma expands capacity for siliconised glass vials with new production lines
SGD Pharma announces the opening of a new siliconisation operation at its state-of-the-art Saint-Quentin Lamotte (SQLM) plant
Media
SGD Pharma announces the appointment of Fabio Invernizzi, General Manager West Business Unit
The BU West includes SGD Pharma’s commercial activities for MEA, North and South America and our manufacturing footprint in Europe
Packaging
SGD Pharma defines 2024 growth strategy as it strives for market leadership
SGD Pharma announces its goal to become the global market leader in primary pharmaceutical glass packaging
Subscribe now